297 related articles for article (PubMed ID: 33023805)
1. Transarterial Chemoembolization Using 100-μm Drug-Eluting Microspheres in Patients with Hepatocellular Carcinoma: A Prospective Study and Midterm Follow-up.
Ou HY; Wu YN; Yu CY; Chen CL; Hsu HW; Weng CC; Leung-Chit Tsang L; Huang TL; Tong YS; Lim WX; Cheng YF
J Vasc Interv Radiol; 2020 Nov; 31(11):1784-1791. PubMed ID: 33023805
[TBL] [Abstract][Full Text] [Related]
2. Transcatheter arterial chemoembolization with doxorubicin-eluting superabsorbent polymer microspheres in the treatment of hepatocellular carcinoma: midterm follow-up.
Dekervel J; van Malenstein H; Vandecaveye V; Nevens F; van Pelt J; Heye S; Laleman W; Van Steenbergen W; Vaninbroukx J; Verslype C; Maleux G
J Vasc Interv Radiol; 2014 Feb; 25(2):248-55.e1. PubMed ID: 24295569
[TBL] [Abstract][Full Text] [Related]
3. Survival Outcomes of Very Small Drug-Eluting Beads Used in Chemoembolization of Unresectable Hepatocellular Carcinoma.
Aal AKA; Moawad S; Lune PV; El Khudari H; Hanaoka MM; Abouldahab N; Gunn AJ; White J; Shoreibah M; Li Y; Saddekni S; Mahmoud K
J Vasc Interv Radiol; 2019 Sep; 30(9):1325-1334.e2. PubMed ID: 31371139
[TBL] [Abstract][Full Text] [Related]
4. Downstaging disease in patients with hepatocellular carcinoma outside of Milan criteria: strategies using drug-eluting bead chemoembolization.
Green TJ; Rochon PJ; Chang S; Ray CE; Winston H; Ruef R; Kreidler SM; Glueck DH; Shulman BC; Brown AC; Durham J
J Vasc Interv Radiol; 2013 Nov; 24(11):1613-22. PubMed ID: 24060436
[TBL] [Abstract][Full Text] [Related]
5. Degradable starch microspheres versus ethiodol and doxorubicin in transarterial chemoembolization of hepatocellular carcinoma.
Niessen C; Unterpaintner E; Goessmann H; Schlitt HJ; Mueller-Schilling M; Wohlgemuth WA; Stroszczynski C; Wiggermann P
J Vasc Interv Radiol; 2014 Feb; 25(2):240-7. PubMed ID: 24291001
[TBL] [Abstract][Full Text] [Related]
6. Korean Multicenter Registry of Transcatheter Arterial Chemoembolization with Drug-Eluting Embolic Agents for Nodular Hepatocellular Carcinomas: Six-Month Outcome Analysis.
Lee M; Chung JW; Lee KH; Won JY; Chun HJ; Lee HC; Kim JH; Lee IJ; Hur S; Kim HC; Kim YJ; Kim GM; Joo SM; Oh JS
J Vasc Interv Radiol; 2017 Apr; 28(4):502-512. PubMed ID: 27856136
[TBL] [Abstract][Full Text] [Related]
7. Degradable starch microspheres transarterial chemoembolization (DSMs-TACE) in patients with unresectable hepatocellular carcinoma (HCC): long-term results from a single-center 137-patient cohort prospective study.
Orlacchio A; Chegai F; Roma S; Merolla S; Bosa A; Francioso S
Radiol Med; 2020 Jan; 125(1):98-106. PubMed ID: 31583558
[TBL] [Abstract][Full Text] [Related]
8. Transarterial Chemoembolization of Hepatocellular Carcinoma Using Radiopaque Drug-Eluting Embolics: How to Pursue Periprocedural Cross-Sectional Imaging?
Ruff C; Grözinger G; Syha R; Elser S; Partovi S; Bitzer M; Horger M; Nikolaou K; Grosse U
J Vasc Interv Radiol; 2019 Mar; 30(3):380-389.e4. PubMed ID: 30819480
[TBL] [Abstract][Full Text] [Related]
9. Safety and Efficacy of Doxorubicin Drug-Eluting Embolic Chemoembolization of Hepatocellular Carcinoma Supplied by Extrahepatic Collateral Arteries.
Lokken RP; Fidelman N; Kolli KP; Kerlan RK
J Vasc Interv Radiol; 2016 Nov; 27(11):1698-1704. PubMed ID: 27397617
[TBL] [Abstract][Full Text] [Related]
10. Transarterial Chemoembolization with Small Drug-Eluting Beads in Patients with Hepatocellular Carcinoma: Experience from a Cohort of 421 Patients at an Italian Center.
Aliberti C; Carandina R; Lonardi S; Dadduzio V; Vitale A; Gringeri E; Zanus G; Cillo U
J Vasc Interv Radiol; 2017 Nov; 28(11):1495-1502. PubMed ID: 28927662
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of doxorubicin drug-eluting bead transarterial chemoembolization in patients with advanced hepatocellular carcinoma.
Prajapati HJ; Dhanasekaran R; El-Rayes BF; Kauh JS; Maithel SK; Chen Z; Kim HS
J Vasc Interv Radiol; 2013 Mar; 24(3):307-15. PubMed ID: 23375519
[TBL] [Abstract][Full Text] [Related]
12. Polyethylene Glycol Epirubicin-Loaded Transcatheter Arterial Chemoembolization Procedures Utilizing a Combined Approach with 100 and 200 μm Microspheres: A Promising Alternative to Current Standards.
Lucatelli P; Argirò R; De Rubeis G; Rocco B; Corradini SG; Corona M; Nardis PG; Saba L; Mennini G; Fiorentino F; Corsi A; Catalano C; Bezzi M
J Vasc Interv Radiol; 2019 Mar; 30(3):305-313. PubMed ID: 30713031
[TBL] [Abstract][Full Text] [Related]
13. Single-center phase II trial of transarterial chemoembolization with drug-eluting beads for patients with unresectable hepatocellular carcinoma: initial experience in the United States.
Reyes DK; Vossen JA; Kamel IR; Azad NS; Wahlin TA; Torbenson MS; Choti MA; Geschwind JF
Cancer J; 2009; 15(6):526-32. PubMed ID: 20010173
[TBL] [Abstract][Full Text] [Related]
14. Comparison of Drug-Eluting Embolics versus Conventional Transarterial Chemoembolization for the Treatment of Patients with Unresectable Hepatocellular Carcinoma: A Cost-Effectiveness Analysis.
Wu X; Chapiro J; Malhotra A; Kothary N
J Vasc Interv Radiol; 2021 Jan; 32(1):2-12.e1. PubMed ID: 33160827
[TBL] [Abstract][Full Text] [Related]
15. Response rate and safety in patients with hepatocellular carcinoma treated with transarterial chemoembolization using 40-µm doxorubicin-eluting microspheres.
Albrecht KC; Aschenbach R; Diamantis I; Eckardt N; Teichgräber U
J Cancer Res Clin Oncol; 2021 Jan; 147(1):23-32. PubMed ID: 32880029
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and Safety of Drug-Eluting Beads Transarterial Chemoembolization by CalliSpheres
Sun J; Zhou G; Xie X; Gu W; Huang J; Zhu D; Hu W; Hou Q; Shi C; Li T; Zhang X; Ji W; Ying S; Peng Z; Zhou J; Yu Z; Ji J; Du H; Guo X; Fang J; Han J; Xu H; Sun Z; Yu W; Shao G; Wu X; Hu H; Li L; Zheng J; Luo J; Chen Y; Cao G; Hu T
Oncol Res; 2020 Feb; 28(1):75-94. PubMed ID: 31558180
[TBL] [Abstract][Full Text] [Related]
17. Bridging Hepatocellular Carcinoma to Transplant: Transarterial Chemoembolization Response, Tumor Biology, and Recurrence after Transplantation in a 12-Year Transplant Cohort.
Sandow T; Pavlus J; Field D; Lacayo E; Cohen E; Lynskey G; Caridi T; Buckley D; Cardella J; Kallakury B; Spies J; Kim AY
J Vasc Interv Radiol; 2019 Jul; 30(7):995-1003. PubMed ID: 31109853
[TBL] [Abstract][Full Text] [Related]
18. A Single-Center Retrospective Comparison of Doxorubicin-Loaded HepaSphere Transarterial Chemoembolization with Conventional Transarterial Chemoembolization for Patients with Unresectable Hepatocellular Carcinoma.
Kucukay F; Badem S; Karan A; Ozdemir M; Okten RS; Ozbulbul NI; Kucukay MB; Unlu I; Bostanci EB; Akdogan M
J Vasc Interv Radiol; 2015 Nov; 26(11):1622-9. PubMed ID: 26321015
[TBL] [Abstract][Full Text] [Related]
19. Transarterial Chemoembolization in a Woodchuck Model of Hepatocellular Carcinoma.
Pritchard WF; Woods DL; Esparza-Trujillo JA; Starost MF; Mauda-Havakuk M; Mikhail AS; Bakhutashvili I; Leonard S; Jones EC; Krishnasamy V; Karanian JW; Wood BJ
J Vasc Interv Radiol; 2020 May; 31(5):812-819.e1. PubMed ID: 32107125
[TBL] [Abstract][Full Text] [Related]
20. Randomized Trial of Hepatic Artery Embolization for Hepatocellular Carcinoma Using Doxorubicin-Eluting Microspheres Compared With Embolization With Microspheres Alone.
Brown KT; Do RK; Gonen M; Covey AM; Getrajdman GI; Sofocleous CT; Jarnagin WR; D'Angelica MI; Allen PJ; Erinjeri JP; Brody LA; O'Neill GP; Johnson KN; Garcia AR; Beattie C; Zhao B; Solomon SB; Schwartz LH; DeMatteo R; Abou-Alfa GK
J Clin Oncol; 2016 Jun; 34(17):2046-53. PubMed ID: 26834067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
